<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360280</url>
  </required_header>
  <id_info>
    <org_study_id>CLNA-018-14S</org_study_id>
    <nct_id>NCT02360280</nct_id>
  </id_info>
  <brief_title>Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression</brief_title>
  <official_title>Intravenous Sub-anesthetic Ketamine Treatment in Treatment-Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      About one-third of depressed patients will not get better after multiple antidepressant
      treatments. This situation put a high burden on patients with depression due to worsening
      quality of life and increasing health care costs. Difficult-to-treat depression might be even
      worse among Veterans given that the frequency of depressive symptoms is 2 to 5 times higher
      than among the general US population. A breakthrough discovery happened in recent years when
      investigators found that one infusion from an old anesthetic named ketamine showed high
      efficacy and rapid antidepressant effect (sometimes within hours) but lasted only up to a
      week. The investigators propose to study if multiple infusions of ketamine can provide
      greater and longer antidepressant effects than one infusion. If that is the case, multiple
      infusions could be an alternative to relieve depressive symptoms that do not response to
      multiple antidepressant drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies have found rapid and highly efficacious antidepressant effects of a single
      ketamine infusion in treatment-resistant depression (TRD). However, a single infusion appears
      insufficient to maintain response as most patients return to previous depressive state within
      a week. The strategy of multiple infusions to increase efficacy and sustain antidepressant
      effects has not yet been systematically evaluated in an randomized control trial (RCT). The
      proposed study is a one-center, interventional, efficacy study designed to determine
      antidepressant outcomes of serial ketamine infusions compared to a single ketamine infusion
      among Veterans with TRD. The investigators have hypothesized that six infusions will be
      superior to a single infusion of ketamine in both decreasing severity of depressive symptoms
      and maintaining response. Participants will be male/female Veterans (18 to 75 years old) of
      any era or military background who suffer from TRD defined as failure to achieve remission
      from at least 2 antidepressant trials of different pharmacological classes. Potential
      participants will be recruited from Mental Health clinics and screened for eligibility using
      a two stage process (phone/chart review, followed by interview). Exclusion criteria includes
      post-traumatic stress disorder, psychosis-related disorder, bipolar disorder,
      alcohol/substance use disorder 6 months prior to screening; unstable medical illness;
      serious/imminent suicidal/homicidal risk; Parkinson's disease, dementia, seizures; traumatic
      brain injury; contraindicated medications (e.g., MAO inhibitors, barbiturates); received
      electroconvulsive therapy (ECT) during current episode; pregnancy/nursing. Baseline
      assessments will be completed 1-2 weeks prior to starting treatment. Participants will be
      randomly assigned to one of two parallel treatment conditions: 1) six ketamine infusions at
      0.5 mg/kg or 2) single ketamine infusion at 0.5 mg/kg preceded by five midazolam infusions at
      0.045 mg/kg. Midazolam was chosen as an active placebo given similar pharmacokinetics and
      dissociative effect profile to ketamine. Each intervention will be provided for a total of
      12-day infusion-phase on a Monday-Wednesday-Friday schedule. The, follow-up visits will occur
      at weekly intervals for the first 4 weeks, at 2-week intervals for the next 8 weeks, and at
      4-week intervals for the remaining 12 weeks or until relapse. The primary end point is the
      Montgomery- sberg Depression Rating Scale (MADRS) score 24 hours following the last infusion
      where the peak antidepressant effects of ketamine occur. Secondary outcomes for the treatment
      phase include remission defined by MADRS&lt;10, and response defined as a reduction in the
      baseline MADRS score 50%. For the follow-up period, durability of antidepressant response
      will be defined by &quot;time to relapse&quot; to a MADRS score &lt;50% of baseline at that visit.
      Independent evaluation of depressive symptom severity and potential covariates of
      antidepressant effect (e.g., pain intensity, level of anxiety) will be ascertained at
      baseline, at several time points during infusion period, and at follow-up. On the day of
      infusion, subjects will arrive in the morning after an overnight fast. Hemodynamic measures
      will be recorded every 10 min for 1 hour beginning 10 min before infusion. Subjects will then
      receive IV infusion over 40 minutes. Severity of depressive symptoms, pain intensity, level
      of anxiety will be obtained before and 24 hours after infusion. Acute dissociative effects,
      manic/hypomanic symptoms, and psychotomimetic effects will be measured 30 minutes before the
      start of each infusion and at the end of infusion (t0+40 mins) and again at t0+120mins and
      t0+180mins. The infusion will be discontinued in the event of significant adverse events.
      Procedures for the subsequent infusions at days 3, 5, 8, 10, and 12 will be identical to
      those of the first infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Actual">March 19, 2019</completion_date>
  <primary_completion_date type="Actual">October 22, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score After 12 Days of Treatment</measure>
    <time_frame>13 days</time_frame>
    <description>Average difference in the Montgomery-Asberg Depression Rating Scale (MADRS) score change between groups. The MADRS has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antidepressant Response Defined as &gt;50% Decrease in MADRS Baseline Score</measure>
    <time_frame>13 days</time_frame>
    <description>Comparing the number of subjects that achieve response between groups as defined above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission Defined as MADRS Score Equal or Less Than 9</measure>
    <time_frame>13 days</time_frame>
    <description>Comparing the number of subjects that achieve remission between groups as defined above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Post-infusion Response to Occurrence of Relapse Defined as &lt;50% of Baseline MADRS Score</measure>
    <time_frame>6 months</time_frame>
    <description>The length of time from post-infusion response until relapse (defined as &gt;50% of MADRS baseline score) assessed for up to 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Treatment-resistant Depression</condition>
  <arm_group>
    <arm_group_label>Six ketamine infusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ketamine infusion preceded by 5 midazolam infusions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketamine</intervention_name>
    <description>sedative</description>
    <arm_group_label>Single ketamine infusion preceded by 5 midazolam infusions</arm_group_label>
    <arm_group_label>Six ketamine infusions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>sedative</description>
    <arm_group_label>Single ketamine infusion preceded by 5 midazolam infusions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Veterans aged 18 to 75 years.

          -  Have a telephone in their home and able to hear telephone conversations.

          -  Must meet current DSM-IV criteria for major depressive disorder (MDD), single or
             recurrent, without psychotic features confirmed by depression subset of the Structured
             Clinical Interview-Clinical Trial for DSM-IV (SCID).

          -  Have score 32 on the Inventory of Depressive Symptomatology-Clinician Rated
             (IDS-C30)for severity of major depressive episode (MDE) at screening.

          -  Current major depressive episode resistant to treatment defined as failure to achieve
             improvement from at least 2 antidepressant trials of different pharmacological
             classes. Systematic evaluation of previous antidepressant trials will be assessed by
             the Antidepressant Treatment History Form (ATHF) .

          -  If applicable, current antidepressant dosages including augmenting agents and/or
             frequency and duration of psychotherapy sessions must remain stable for at least 6
             weeks prior to beginning of the study.

        Exclusion Criteria:

          -  Inability to speak English.

          -  Inability or unwillingness to provide written informed consent.

          -  Moderate/severe cognitive impairment by Mini Mental State Examination (MMSE) scores
             27.

          -  Current or lifetime DSM-V criteria for post-traumatic stress disorder (PTSD), acute
             stress disorder, psychosis-related disorder, bipolar disorder I or II disorder,
             substance-induced mood disorder, any mood disorder due to a general medical condition
             or any Axis I disorder other than MDD as the primary presenting problem.

          -  History of moderate or severe traumatic brain injury, Parkinson's disease, dementia of
             any type, multiple sclerosis, seizures or other central nervous system (CNS) related
             disorders.

          -  History of comorbid substance disorder within 6 months of assessment plus positive
             urine toxicology screen test during baseline assessments.

          -  Clinically unstable medical illness that could compromise the patient's ability to
             tolerate or likely interfere with the study procedures (e.g., history of or current
             myocardial ischemia or arrhythmias, congestive heart failure, severe pulmonary, renal,
             or hepatic disease, uncontrolled hypertension).

          -  Current or within less than 14 days use of barbiturates or monoamine oxidase
             inhibitors (MAOi).

          -  For women: pregnancy (confirmed by lab test), initiation of female hormonal treatments
             within 3 months of screening, or inability/ unwillingness to use a medically accepted
             contraceptive method during the study.

          -  Imminent risk of suicidal/homicidal ideation and/or behavior with intent and/or plan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo R Shiroma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis VA Health Care System, Minneapolis, MN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>February 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <results_first_submitted>October 21, 2019</results_first_submitted>
  <results_first_submitted_qc>November 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2019</results_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depressive Disorder, Treatment-Resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02360280/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02360280/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from April 2015 through October 2018</recruitment_details>
      <pre_assignment_details>Four subjects were enrolled but not assigned to treatment. They voluntarily decided to decline participation for logistical issues.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Six Ketamine Infusions</title>
          <description>Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
ketamine: sedative</description>
        </group>
        <group group_id="P2">
          <title>Single Ketamine Infusion Preceded by 5 Midazolam Infusions</title>
          <description>Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
ketamine: sedative
midazolam: sedative</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Six Ketamine Infusions</title>
          <description>Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
ketamine: sedative</description>
        </group>
        <group group_id="B2">
          <title>Single Ketamine Infusion Preceded by 5 Midazolam Infusions</title>
          <description>Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
ketamine: sedative
midazolam: sedative</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="13.8"/>
                    <measurement group_id="B2" value="51.2" spread="12.5"/>
                    <measurement group_id="B3" value="52.7" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MADRS</title>
          <description>The Montgomery-Asberg Depression Rating Scale (MADRS) has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.88" spread="7.79"/>
                    <measurement group_id="B2" value="33.82" spread="5.11"/>
                    <measurement group_id="B3" value="34.32" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IDS-C</title>
          <description>The Inventory of Depressive Symptomatology—Clinician Rated (IDS-C) is a 30-item questionnaire designed to assess the severity of depressive symptoms.The seven-day period prior to assessment is the usual time frame for assessing symptom severity. Ranges are 0-11=None, 12-23=Mild, 24-36=Moderate, 37-46=Severe, 47-84=Very Severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="3.9"/>
                    <measurement group_id="B2" value="39.8" spread="7.3"/>
                    <measurement group_id="B3" value="38.4" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BAI</title>
          <description>Beck Anxiety Inventory (BAI) contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely). Higher total scores indicate more severe anxiety symptoms. 0–7: minimal anxiety; 8-15: mild anxiety; 16-25: moderate anxiety; 26-63: severe anxiety.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.32" spread="13.62"/>
                    <measurement group_id="B2" value="10.57" spread="6.88"/>
                    <measurement group_id="B3" value="11.31" spread="10.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI</title>
          <description>The Clinical Global Impression – Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.32" spread="0.56"/>
                    <measurement group_id="B2" value="5.14" spread="0.64"/>
                    <measurement group_id="B3" value="5.22" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NRS</title>
          <description>The NRS for pain is a unidimensional measure of pain intensity in the last 24 hours. An 11‐point numeric scale with 0 representing one pain extreme (e.g., “no pain”) and 10 representing the other pain extreme (e.g., “pain as bad as you can imagine” and “worst pain imaginable”).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.16" spread="2.49"/>
                    <measurement group_id="B2" value="3.37" spread="2.09"/>
                    <measurement group_id="B3" value="3.27" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score After 12 Days of Treatment</title>
        <description>Average difference in the Montgomery-Asberg Depression Rating Scale (MADRS) score change between groups. The MADRS has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).</description>
        <time_frame>13 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Six Ketamine Infusions</title>
            <description>Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
ketamine: sedative</description>
          </group>
          <group group_id="O2">
            <title>Single Ketamine Infusion Preceded by 5 Midazolam Infusions</title>
            <description>Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
ketamine: sedative
midazolam: sedative</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score After 12 Days of Treatment</title>
          <description>Average difference in the Montgomery-Asberg Depression Rating Scale (MADRS) score change between groups. The MADRS has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="17.2" upper_limit="24.8"/>
                    <measurement group_id="O2" value="17.2" lower_limit="13.2" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antidepressant Response Defined as &gt;50% Decrease in MADRS Baseline Score</title>
        <description>Comparing the number of subjects that achieve response between groups as defined above.</description>
        <time_frame>13 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Six Ketamine Infusions</title>
            <description>Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
ketamine: sedative</description>
          </group>
          <group group_id="O2">
            <title>Single Ketamine Infusion Preceded by 5 Midazolam Infusions</title>
            <description>Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
ketamine: sedative
midazolam: sedative</description>
          </group>
        </group_list>
        <measure>
          <title>Antidepressant Response Defined as &gt;50% Decrease in MADRS Baseline Score</title>
          <description>Comparing the number of subjects that achieve response between groups as defined above.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission Defined as MADRS Score Equal or Less Than 9</title>
        <description>Comparing the number of subjects that achieve remission between groups as defined above</description>
        <time_frame>13 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Six Ketamine Infusions</title>
            <description>Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
ketamine: sedative</description>
          </group>
          <group group_id="O2">
            <title>Single Ketamine Infusion Preceded by 5 Midazolam Infusions</title>
            <description>Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
ketamine: sedative
midazolam: sedative</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Defined as MADRS Score Equal or Less Than 9</title>
          <description>Comparing the number of subjects that achieve remission between groups as defined above</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Post-infusion Response to Occurrence of Relapse Defined as &lt;50% of Baseline MADRS Score</title>
        <description>The length of time from post-infusion response until relapse (defined as &gt;50% of MADRS baseline score) assessed for up to 6 months.</description>
        <time_frame>6 months</time_frame>
        <population>The overall number of participants in each intervention corresponds to the total number of subjects that achieve response at the end of six infusions.</population>
        <group_list>
          <group group_id="O1">
            <title>Six Ketamine Infusions</title>
            <description>Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
ketamine: sedative</description>
          </group>
          <group group_id="O2">
            <title>Single Ketamine Infusion Preceded by 5 Midazolam Infusions</title>
            <description>Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
ketamine: sedative
midazolam: sedative</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Post-infusion Response to Occurrence of Relapse Defined as &lt;50% of Baseline MADRS Score</title>
          <description>The length of time from post-infusion response until relapse (defined as &gt;50% of MADRS baseline score) assessed for up to 6 months.</description>
          <population>The overall number of participants in each intervention corresponds to the total number of subjects that achieve response at the end of six infusions.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="0" upper_limit="16.81"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0" upper_limit="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The time frame of data collection was 3 years and 8 months (from April 2015 through December 2018). Each participant was assessed for up to 28 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Six Ketamine Infusions</title>
          <description>Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
ketamine: sedative</description>
        </group>
        <group group_id="E2">
          <title>Single Ketamine Infusion Preceded by 5 Midazolam Infusions</title>
          <description>Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
ketamine: sedative
midazolam: sedative</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent headaches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Increased in blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ringing in ears</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General malaise</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sleeping too much</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Poor concentration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Decreased energy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent urination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of sexual desire</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Trouble achieving orgasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Trouble with erections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Increased perspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paulo R. Shiroma</name_or_title>
      <organization>Minneapolis VA Medical Center</organization>
      <phone>612-467-2264</phone>
      <email>paulo.shiroma@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

